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AbstrACt 
Introduction Patients with end-stage kidney disease 
requiring maintenance haemodialysis treatment 
experience a dramatic cardiovascular morbidity 
and mortality. Due to the high atherosclerotic and 
arteriosclerotic burden and profound alterations in 
haemostasis, they frequently suffer and die from both 
thromboembolic and bleeding events. This is a particular 
concern in patients on haemodialysis with atrial fibrillation 
(AF). Controlled trials on the optimal anticoagulation in 
patients with AF on haemodialysis are not available. 
The randomised controlled phase IIIb AXADIA–AFNET 8 
trial will evaluate the safety and efficacy of the factor 
Xa inhibitor apixaban in patients with AF requiring 
haemodialysis.
Methods and analysis A total of 222 patients will be 
randomised in an open-labelled, 1:1 design to receive 
either apixaban 2.5 mg twice daily or dose-adjusted 
vitamin K antagonist therapy (target international 
normalised ratio 2.0–3.0). All patients will be treated and 
followed up for a minimum of 6 months up to a maximum 
of 24 months. The primary outcome is major or clinically 
relevant, non-major bleedings or death of any cause. 
Secondary outcomes include stroke, cardiovascular death 
and other thromboembolic events, thus exploring the 
efficacy of apixaban. The first patient was randomised in 
June 2017.
Ethics and dissemination The study protocol 
was approved by the Ethical Committee of the 
Landesaertzekammer, Westfalen-Lippe and the Medical 
Faculty of the University of Muenster, Muenster, Germany 
(reference number: 2016-598 f-A). Written informed 
consent will be obtained from all patients prior to study 
participation, including their consent for long-term follow-
up. AXADIA–AFNET 8 is an investigator-initiated trial. 
Sponsor is AFNET, Muenster, Germany. Study findings 
will be disseminated to Bristol-Myers Squibb, Munich, 
Germany, and Pfizer, Berlin, Germany, to the participating 
centres, at research conferences and in peer-reviewed 
journals.
trial registration numbers NCT02933697,Pre-results.
IntroduCtIon 
More than 15 million people in the USA and 
more than 6 million people in Germany suffer 
from chronic kidney disease (CKD), with an 
expected increase in ageing populations with 
more comorbidities such as diabetes or hyper-
tension.1–6 Approximately 120 000 patients 
are alive in CKD stage G4 in Germany, and 
85 000 in stage G5D (end-stage kidney disease 
(ESKD) on peritoneal or haemodialysis).5 
CKD is an important driver of cardiovascular 
mortality,4 illustrating the need for optimal 
cardiovascular protection in patients with 
CKD. Atrial fibrillation (AF) is common in 
CKD affecting ca. 10%–25% of patients with 
end-stage CKD.7–10 
Patients with CKD are at high risk of throm-
boembolic events and bleedings.7 8 Concor-
dantly, ischaemic and haemorrhagic stroke 
strengths and limitations of this study
 ► This randomised controlled phase IIIb trial will 
provide important information about the safety of 
apixaban compared with vitamin K antagonist in pa-
tients on haemodialysis and with non-valvular atrial 
fibrillation.
 ► The secondary outcome will evaluate the efficacy 
of apixaban compared with vitamin K antagonist in 
preventing thromboembolic events.
 ► A pharmacokinetic substudy enrolling 28 patients 
will investigate whether a reduced dosage of 2.5 mg 
apixaban in haemodialysis patients results in simi-
lar plasma levels of apixaban as the recommended 
5 mg dose for patients without renal insufficiency, as 
preliminary findings suggest.
 ► This trial will provide evidence which type of antico-
agulation shall be preferred in patients on haemodi-
alysis and with non-valvular atrial fibrillation.
 ► The lack of a control arm without any oral anticoag-
ulation is a limitation of the study design.
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are typical and frequent complication in ESKD: data 
from the large US Renal Data System showed a stroke 
incidence of 15.1% in haemodialysis patients compared 
with 9.6% in other stages of CKD, and 2.6% in a control 
cohort without CKD; stroke-related 2-year mortalities of 
74%, 55% and 28%, respectively, have been reported 
from some analyses.11 Oral anticoagulation with vitamin 
K antagonists (VKAs) can prevent most thromboem-
bolic events in patients with AF at risk of stroke.12 Non 
vitamin K antagonist oral anticoagulants (NOACs) have a 
similar effectiveness with lower risk of bleeding, particu-
larly intracranial bleeds.13
The effectiveness and safety of VKA and NOACs in 
patients with non-valvular AF is well established, including 
in patients with mild or moderate CKD.12–14 Unfortu-
nately, there is very little evidence on the safety and effi-
cacy of NOACs in patients with AF and end-stage CKD.
Bleeding rates in CKD patients on dialysis treated with 
VKAs are high,15–19 illustrating the need for safe anti-
coagulation in these patients.20 In a retrospective anal-
ysis of the ARISTOTLE data,21 the reduction in major 
bleedings was greatest in patients in advanced CKD on 
apixaban compared with patients on VKA. Apixaban or 
other NOACs have not been evaluated in patients with 
AF on haemodialysis. To address this evidence gap, the 
'Safety Study Assessing Oral Anticoagulation with Apix-
aban versus Vitamin K Antagonists in Patients with Atrial 
Fibrillation and End-Stage Kidney Disease (ESKD) on 
Chronic Hemodialysis Treatment’ (AXADIA–AFNET 8) 
will compare the safety of apixaban to VKA therapy in 
CKD patients on dialysis.
MEthod And AnAlysIs
Primary and secondary objective
The primary objective is to assess the safety of apixaban 
compared with VKA therapy (carried out using the local 
VKA phenprocoumon) in patients with AF and ESKD 
on maintenance haemodialysis treatment. The primary 
hypothesis of the study is that apixaban has a superior 
safety profile in patients with AF and ESKD on haemo-
dialysis compared with phenprocoumon, while providing 
similar efficacy in reducing thromboembolic events. The 
secondary objective is to compare the efficacy of apix-
aban with VKA regarding prevention of thromboembolic 
events in patients with ESKD on haemodialysis and AF.
Patients, study design and randomisation
AXADIA–AFNET 8 is an investigator-initiated, prospec-
tive, parallel-group, multicentre trial conducted in 25–30 
German study sites (online supplementary appendix 
A). Adult patients aged ≥18 years with ESKD on mainte-
nance haemodialysis treatment three times a week and 
an indication for oral anticoagulation due to non-valvular 
AF will be centrally and electronically randomised into 
two treatment arms: apixaban or phenprocoumon (1:1 
allocation). As phenprocoumon needs constant inter-
national normalised ratio (INR) control, the study will 
be performed with an open-label administration of the 
study drugs. The randomisation will be stratified by two 
conditions: First, patients with a previous thromboembo-
lism including any type of ischaemic stroke that meet the 
above criteria can be included after >3 months if they are 
not severely handicapped as indicated by a value of 0 or 
1 on the modified Rankin scale22 and will be stratified to 
assure equal distribution within the groups. For further 
details on inclusion and exclusion criteria, see Box 1.
Second, patients actually on phenprocoumon therapy 
can also be randomised; however, their proportion will be 
limited to a maximum 50% of the entire cohort to ensure 
that AXADIA-AFNET 8 also provides safety information 
in anticoagulation-naive patients. This condition will also 
be concerned as stratification in the randomisation proce-
dure. In overview, patients’ recruitment and allocation is 
displayed in figure 1 in accordance to the Consolidated 
Standards of Reporting Trials (CONSORT) standard.
study ProCEdurEs
treatment with apixaban
Patients randomised to apixaban will be treated with 
apixaban 2.5 mg twice a day. Apixaban will be provided 
to the study sites by Bristol-Myers Squibb in specific 
labelled bottles of 200 tablets. Apixaban was chosen as 
its mode of excretion is mainly via the bile, theoretically 
enabling stable plasma levels independent of haemo-
dialysis. In addition, a subanalysis of the effect of CKD 
in the ARISTOTLE trial suggested that the relative 
bleeding risk of apixaban compared with VKA was lower 
in patients with advanced CKD (estimated glomerular 
filtration rate (eGFR) 25–50 mL/min).21 The study drug 
will be dispensed to the patient at the study site. The 
patient will be instructed to take the study drug with an 
approximately 12 hours gap apart. The compliance will 
be controlled by pill count and treatment interruptions 
will be documented and tracked centrally in the e-trial 
management system.
treatment with phenprocoumon
Patients randomised to VKA will be treated with phenpro-
coumon, the locally used VKA in Germany, with a target 
INR of 2.0–3.0. Patients will receive a prescription for 
phenprocoumon at the study site on the day of rando-
misation. According to measured INR and the summary 
of product characteristics (SmPC), the investigator will 
recommend an individually adjusted dose to the patient. 
Weekly INR controls will be carried out to ensure the 
compliance to the target INR.
The protocol provides detailed recommendations for 
anticoagulation during haemodialysis (online supple-
mentary appendix B).
All subjects will be treated with the study drug for at 
least 6 months. Subjects who are included early during 
the trial will stay under treatment in the study until the 
last subject has completed the treatment period of 6 
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months. This will probably lead to a study participation of 
about 24 months for the first subjects enrolled (figure 2).
timelines and follow-up
Screening period (up to 7 days before baseline visit)
In presence of the study staff, all patients must give full 
written informed consent during the screening period 
(online supplementary appendix C). Insurance informa-
tion covering any harm resulting from the study drug is 
handed out to the participant. Inclusion and exclusion 
criteria will be checked. Demographic and anthropo-
metric data, renal status, concomitant diseases and medi-
cation, and data on haemodialysis will be documented. 
Blood count, INR evaluation, ECG recording and risk 
stratification will be performed.
Baseline visit
Adherence to inclusion and exclusion criteria will 
be checked. Data on haemodialysis and concomitant 
medication will be documented. If applicable, blood 
parameters, thromboembolic and bleeding events, 
adverse events (AEs) and events of special interest will 
be recorded. Patients will be randomised. EQ-5D ques-
tionnaire will be completed by the patient. For subjects 
randomised for phenprocoumon, INR evaluation will be 
performed.
Follow-up visits
During the monthly follow-up visits, data on haemodial-
ysis and INR evaluation (for subjects on phenprocoumon) 
will be documented. If applicable, changes in concomi-
tant medication, blood parameters, thromboembolic and 
bleeding events, AEs and events of special interest will be 
documented. EQ-5D questionnaire will be completed on 
visits 6, 12 and 18 by the patient. Adherence to study drug 
will be performed on a quarterly basis.
End of treatment
Data on haemodialysis, concomitant medication, 
concomitant diseases and adherence to study drug will 
be documented. ECG recording will be performed. 
EQ-5D questionnaire will be completed by the patient. 
For subjects on phenprocoumon, INR will be measured. 
If applicable, thromboembolic and bleeding events, AEs 
and events of special interest will be recorded.
End of study (30 days after end of treatment)
Data on concomitant medication, blood parameters, 
thromboembolic and/or bleeding events, AEs and events 
of special interest will be documented.
AE reporting
An AE is defined as any untoward medical occurrence 
or worsening of a pre-existing medical condition in the 
patient administered the study drug and that does not 
necessarily have a causal relationship with the study drug 
(ie, apixaban or phenprocoumon). All AEs, regardless 
of related or not related to the study drug, which occur 
from screening to end of study will be collected and 
box 1 Inclusion and exclusion criteria
Inclusion criteria
 ► End-stage kidney disease with chronic haemodialysis treatment 
three times per week (with about 4 hours per dialysis).
 ► Chronic (ie, repeated) paroxysmal, persistent or permanent AF doc-
umented by standard or Holter ECG on at least two separate days 
before (or apart from) haemodialysis procedures.
 ► Increased risk of stroke or systemic embolism identi-
fied by a CHA2DS2-VASc score of  ≥2  as an indication for oral 
anticoagulation.
 ► Patients with a previous ischaemic stroke that meet the above cri-
teria can be included after >3 months if not severely handicapped 
(modified Rankin scale 0 or 1 of 622).
 ► Males and females, aged 18 or older.
 ► Signed written informed consent.
Exclusion criteria at baseline
 ► AF or atrial flutter due to reversible causes (eg, thyrotoxicosis, 
pericarditis).
 ► Patients with a new onset of haemodialysis within the last 
three months.
 ► Clinically significant (moderate or severe) aortic and mitral stenosis.
 ► Conditions other than AF that require chronic anticoagulation (eg, a 
prosthetic mechanical heart valve).
 ► Active infective endocarditis.
 ► Any planned interventional or surgical AF or atrial flutter ablation 
procedure.
 ► Any active bleeding.
 ► A serious bleeding event in the previous six months before 
screening.
 ► Inadequately controlled (HbA1c levels>8.5%) or untreated diabetes.
 ► History of malignant neoplasms at high risk of current bleeding (see 
summary of product characteristics of study drugs).
 ► Known indication for treatment with NSAIDs (ASA up to 100 mg per 
day is allowed).
 ► Impaired liver function, for example, caused by active infection with 
HIV, HBV or HCV, hepatitis or other liver damage.
 ► Any type of stroke within 3 months prior to baseline.
 ► Valvular heart disease requiring surgery.
 ► A high risk of bleeding (eg, active peptic ulcer disease, a platelet 
count of <100 000/mm3 or haemoglobin level of<8 g/dL).
 ► Documented haemorrhagic tendencies or blood dyscrasias.
 ► Current alcohol or drug abuse.
 ► Life expectancy of <1 year.
 ► Indication for dual platelet inhibition at baseline (ASA≤100 mg/day is 
allowed; clopidogrel is at baseline excluded at any dose, during trial 
allowed for up to 30 days).
 ► Any disease or circumstances on account of which the sub-
ject should not participate in the study in the opinion of the 
investigator.
 ► Psychiatric condition that might limit the participation in the study 
and/or that lead to the assumption that the ability to completely un-
derstand the consequences of consent is missing.
 ► Pregnant or breastfeeding women.
 ► Documented intolerance to one or both active substances of the 
study drugs.
AF, atrial fibrillation; ASA, acetylsalicylic acid; CHA2DS2-VASc score, congestive 
heart failure/LV dysfunction, hypertension, age ≥75 years, diabetes, previous 
stroke/transischaemic attack/thromboembolism, vascular disease, age 65–74, 
sex category (female); HBV, hepatitis B virus; HCV, hepatitis C virus; NSAIDs, 
non-steroidal anti-inflammatory drugs.
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seriousness, severity and causality will be assessed by the 
investigator. All AEs will be reported in detail in the elec-
tronic case report form (eCRF).
Primary, secondary and other outcomes
Primary outcome is a composite of major and clini-
cally relevant, non-major bleeding in accordance to the 
International Society of Thrombosis and Hemostasis (ISTH) 
consensus23 as well as shunt/fistula bleedings in dialysis 
patients on anticoagulation. The detailed list of all safety 
end points is given in Box 2.
Secondary outcomes include thromboembolic events. 
Details of the secondary outcomes and other outcomes 
are given in Box 2.
study discontinuation
In accordance to the SmPC of apixaban,24 the following 
medications are prohibited throughout the whole trial 
and will lead to study discontinuation: Strong inhibitors of 
both cytochrome P450 3A4 and P-glycoprotein. Further-
more, regular intake of non-steroidal anti-inflammatory 
drugs (NSAIDs) or cyclo-oxygenase-2 inhibitors, except 
Figure 1 Patients' enrolment and allocation in accordance to the Consolidated Standards of Reporting Trials (CONSORT) 
stand is displayed. Of note, two stratifications are implemented in the randomisation procedure: first, for patients who suffered 
from a previous stroke or systemic thromboembolic (TE) event which must have occurred at least 3 months before enrolment 
without residual limitations (only value of 0 or 1 on the modified Rankin scale). Second, for patients who were already assigned 
to an oral anticoagulation whose proportion will be limited to 50% of the entire study cohort. INR, international normalised ratio. 
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for acetylsalicylic acid (ASA) up to 100 mg/day, lead also 
to study discontinuation.
Other reasons for discontinuation are elective surgical 
interventions which demands interruption of study drug 
intake for >3 weeks; planned kidney transplantation 
within the next three days; pregnancy; and any AE or 
clinical relevant change in blood parameters because of 
which the responsible physician does not consider a study 
drug continuation as beneficial for the patient.
All patients who prematurely discontinue the study 
drug treatment are asked to perform the end of treat-
ment visit.
data management and auditing
An interactive web response system will be used to allo-
cate patients to the two treatment groups. Study staff 
will record patients’ data on the eCRF. All study-related 
information about participants will be stored securely 
and kept strictly confidential. All study sites will be super-
vised by a monitor throughout the entire study duration. 
One visit takes place before enrolment of the first patient 
to clarify all prerequisites and assure the medical and 
formal instruction of investigators and the knowledge to 
the protocol. On-site monitoring takes place on a regular 
basis and includes review of protocol compliance, check 
of the complete and correct entry into the eCRF, and 
correct handling and storage of the study drug.
Patient and public involvement
Neither public nor patients were involved in the design or 
conduct of the study. Study results will be disseminated to 
the patients by a circular letter.
Pharmacokinetic substudy
The dosing of apixaban with 2.5 mg twice daily was 
chosen from pharmacokinetic modelling from plasma 
levels of some individuals with dialysis-dependent renal 
failure. Moreover, it is based on the currently recom-
mended dose for apixaban in patients with CKD stage 
G4 according to the European label.24 Furthermore, 
results from a small pivotal study were published indi-
cating that a dosage of 2.5 mg apixaban twice daily in 
dialysis-dependent patients will result in similar plasma 
levels as the higher dosage of 5 mg twice daily in healthy 
individuals.25 To confirm these preliminary findings, 
a pharmacokinetic substudy will be conducted in this 
trial with 28 patients randomised to apixaban to deter-
mine plasma serum levels of apixaban prior to and 
after haemodialysis, and also after a short (2 days) and 
a long (3 days) dialysis interval (figure 3). The study 
staff will obtain written consent from patients willing to 
participate in the substudy. In these patients, two blood 
samples will be collected, one sample before and one 
after haemodialysis. Apixaban levels will be measured at 
a central laboratory in Richmond, Virginia, USA.
sample size calculations
One recent publication reported bleeding rates in a 
similar (but not identical) setting in haemodialysis 
patients treated with dabigatran and rivaroxaban, ASA 
and VKAs.26 Based on these data and using similar 
end point definitions especially for bleedings, it was 
assumed for the AXADIA-AFNET 8 study setting that 
apixaban would have comparable bleeding rates as ASA 
in dialysis patients. The latter assumption is supported by 
the AVERROES trial27 in which apixaban and ASA were 
compared in a cohort of non-dialysis-depended patients 
who were not considered suitable for oral anticoagulation 
due to a high bleeding risk: in that trial including patients 
with a comparable high risk as here, the rates of major 
and clinically relevant, non-major bleedings were similar 
in the apixaban group and the ASA group. Based on these 
data, we expect an hazard rate (HR) for the combination 
of major and clinically relevant non-major bleedings of 
0.0789 per months for apixaban and 0.131 for phenpro-
coumon. According to these figures, a total sample size of 
166 patients will be sufficient to demonstrate superiority 
of apixaban treatment with 80% power with respect to 
the primary end point, and also with respect to clinically 
Figure 2 Timelines and regular visits during the study period are presented. After screening visit, two qualifying ECGs showing 
atrial fibrillation must be sent to a central appraisal and, if all other inclusion and exclusion criteria match, randomisation 
and inclusion can be performed within 7 days. Afterwards, monthly visits during the regular dialysis sessions will have to 
be documented. When the last recruited patient has been on treatment for 6 months, the study will be terminated (end of 
treatment). All patients will be followed up for another 30 days after which the study will be completed (end of study).
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relevant, non-major bleedings only. Including a 20% secu-
rity margin and about 10% drop-outs, AXADIA-AFNET 8 
will randomise 222 patients (figure 1).
statistics
The full analysis set will include all randomised patients 
with and without any kind of protocol violations, applying 
the intention-to-treat-principle. In the per-protocol popu-
lation, patients with relevant protocol violations will be 
excluded. The safety set will consist of all patients who 
were randomised and received at least one dose of the 
study drug, applying the as-treated principle.
Continuous variables will be presented group-wise by 
means±SD and tested by t-tests for independent samples. 
Skewed data will be transformed towards normality or 
tested by non-parametric U tests. Categorical variables will 
be presented by counts and percentages and compared 
by χ2 tests or Fisher’s exact tests as appropriate.
In the primary statistical analysis, the treatments will be 
compared with respect to the primary safety end point 
time to first occurrence of a major or clinically relevant, 
non-major bleeding or death of any cause. Let HR denote 
the corresponding HR of the apixaban treatment versus 
VKA (phenprocoumon) treatment. Two statistical null 
hypotheses will be tested:
H0
Superiority: HR ≥1 versus H1
Superiority: HR <1 (proof of 
superiority of apixaban)
H0
Non-Inferiority: HR ≥1.25 vs. H1
Non-Inferiority: HR <1.25 
(proof of non-inferiority of apixaban)
The multiple one-sided significance level is set to 
α=2.5%. A sequentially rejective multiple test procedure 
will be applied that controls the familywise error rate 
in the strong sense at prespecified significance level α. 
The hypothesis H0
Non-Inferiority is defined to be the initial 
hypothesis and is assigned the local significance level 
α(H0
Non-Inferiority)=2.5%. If the initial hypothesis H0
Non-Infe-
riority is rejected, subsequently the hypothesis H0
Superiority is 
tested on local significance level 2.5%. The primary statis-
tical analysis provides confirmatory statistical evidence.
The superiority test will be performed in the full anal-
ysis set that consists of all randomised patients, including 
patients with any kind of protocol violations, applying the 
intention-to-treat principle. The non-inferiority test will 
additionally be performed in the per-protocol popula-
tion, excluding patients with relevant protocol violations. 
Statistically significant non-inferiority will be claimed only 
if the result is supported both in the intention-to-treat 
analysis and the per-protocol analysis.
The primary analysis will be up to the first occurrence 
of the end point. Beyond the above primary statistical 
analysis of the primary end point, an extended analysis 
of the primary end point will additionally take recurrent 
events into regard and will be performed by fitting an 
Anderson-Gill model with robust estimation of coeffi-
cients and variance terms to the data. From all models, 
HRs and two-sided 95% confidence limits will be calcu-
lated and discussed whether safety risks can be derived 
based on the results. Statistical analyses of the primary 
end point will be repeated in the safety population that 
consists of all patients who received at least one dose of 
the study drug, applying the as-treated principle.
The secondary end points, both events of special 
interest and the composite end point (Box 2) are the 
efficacy end points and will be analysed on an inten-
tion-to-treat-basis by descriptive statistics only due to the 
small sample size which will probably not be sufficiently 
large enough to demonstrate superiority. Adjusted Cox 
proportional hazard models, Anderson-Gill models and 
the described sensitivity analyses will be performed as 
described above. No adjustment for multiplicity will be 
provided as the efficacy analysis is secondary behind the 
primary safety analysis.
box 2 End points
Primary outcome: Composite of major and clinically relevant, non-ma-
jor bleeding events and death of any cause
Major bleeding events as defined by ISTH23 and complemented by other 
serious bleeding events:
 ► Fatal bleeding.
 ► Bleeding that is symptomatic and occurs in a critical area or organ, 
such as intracranial, intraspinal, intraocular, retroperitoneal, peri-
cardial, in a non-operated joint or intramuscular with compartment 
syndrome.
 ► Bleeding causing a fall in haemoglobin level of 20 g/L (1.24 mmol/L) 
or more.
 ► Bleeding leading to transfusion of two or more units of whole blood 
or red cells, with temporal association within 24–48 hours to the 
bleeding.
 ► Bleeding that requires an operation or endoscopic intervention (ar-
throscopic, endovascular or a haemarthrosis).
Clinically relevant, non-major bleeding (according to ISTH consensus,23 
complemented by relevant bleeding events in dialysis patients):
 ► Bleeding resulting in hospitalisation or prolonged hospitalisation.
 ► Bleeding requiring medical or surgical treatment by a physician.
 ► Bleeding leading to a modification of the given anticoagulant therapy.
 ► Gastrointestinal bleeding proven by endoscopy or surgery.
 ► Shunt-induced/catheter-induced bleeding.
 ► Bleeding between dialysis sessions.
 ► Prolonged bleeding requiring compression for >30 min after dialysis 
needle removal.
Efficacy events
 ► Myocardial infarction.
 ► Ischaemic stroke.
 ► All-cause death.
 ► Cardiovascular death.
 ► Deep vein thrombosis and/or pulmonary embolism.
Composite end point
 ► Myocardial infarction.
 ► Ischaemic stroke.
 ► All-cause death.
 ► Deep vein thrombosis and/or pulmonary embolism.
Events of special interest
 ► Dialysis shunt thrombosis.
 ► Clotting of dialysis membrane.
Pharmacokinetics (substudy in 28 apixaban patients)
 ► Apixaban plasma level prior and after haemodialysis, see figure 3.
ISTH, International Society on Thrombosis and Haemostasis.
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The Data and Safety Monitoring Board will adjudi-
cate the following safety and efficacy end points: major 
bleeding, clinically relevant, non-major bleeding, 
myocardial infarction, ischaemic stroke, all-cause death, 
cardiovascular death and deep vein thrombosis and/or 
pulmonary embolism (Box 2).
Ethics and dissemination
AXADIA-AFNET 8 is an investigator-initiated trial which 
is conducted by the Kompetenznetz Vorhofflimmern 
e.V. (Atrial Fibrillation NETwork, AFNET), Muenster, 
Germany, as responsible sponsor. The study is financed 
by Bristol-Myers Squibb (BMS, Munich, Germany) and 
Pfizer (Berlin, Germany) as specified in the supplement 
(online supplementary appendix D).
AXADIA-AFNET 8 is registered at http://www. clinical-
trials. gov (NCT02933697, registration date 14 October 
2016; pre-results) and at EudraCT (2015-005503-84).
The study protocol (CV185-435, V.1.2, 18 August 2017) 
was approved by the Ethical Committee of the Landesaer-
ztekammer (Medical Association) Westfalen-Lippe and 
the Medical Faculty of the University of Muenster, Muen-
ster, Germany (reference number: 2016–598 f-A) as lead 
ethics committee and by ethics committees at all partici-
pating sites. Protocol amendments will be communicated 
to the study sites by the sponsor.
The design, conduct and analysis of the study as well as 
decisions on publication of study results will be led by a 
steering committee (online supplementary appendix E). 
The steering committee has full access to the data set. A 
Data and Safety Monitoring Board will supervise this study 
and will be blinded to treatment groups (online supple-
mentary appendix F). All safety and efficacy end points 
will be evaluated by an independent Endpoint Assess-
ment Committee blinded to treatment group, eCRF, e-trial 
system, data capture and monitoring (online supplemen-
tary appendix G). The trial sponsor has no role in collec-
tion, analysis and interpretation of data, or decision to 
submit results.
Study findings will be disseminated to Bristol-Myers 
Squibb, Munich, Germany, and Pfizer, Berlin, Germany, 
to the participating centres, at research conferences, and 
in peer-reviewed journals.
dIsCussIon
Patients with CKD are well known to suffer from a high 
overall morbidity and mortality which is mainly driven by 
cardiovascular causes. This concerns especially patients 
in the advanced CKD stages G3 to G5 as demonstrated 
impressively by estimated 2.2 million deaths worldwide 
which are attributed only to patients in these stages.4 
These deleterious effects are caused, on the one hand, 
by the underlying diseases leading to kidney disease, on 
the other hand, by alterations induced by CKD itself, 
which lead to rapid progress in atherosclerosis and 
Figure 3 The design of a pharmacokinetic (PK) substudy is given here. In total, 28 patients who must give additional written 
informed consent will be examined regarding their apixaban levels before and after dialysis. Of these, apixaban levels will be 
assessed in 14 patients after the 3-day-long dialysis-free interval, and in another 14 patients after the short 2-day dialysis-free 
interval. Since patients on haemodialysis are regularly treated in two shifts (AM and PM), the 14 patients will be splitted again 
and apixaban levels will be assessed in 7 patients of the AM shift and another 7 patients of the PM shift. This might be of 
interest since patients will be instructed to take their apixaban between 07:00 to 08:00 AM and PM, independent from the start 
of their dialysis shifts, so plasma levels may vary between the groups.
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arteriosclerosis but also to profound changes in haemo-
stasis. Apart from these disease-related origins, the poor 
prognosis of patients with CKD—and especially those 
with ESKD—is, moreover, also attributed to a ‘therapeutic 
nihilism’ of many treating physicians: many AF patients 
with advanced CKD do not receive medications or treat-
ments that have been proven or are at least considered to 
be beneficial in the general population.28
oral anticoagulation in advanced kidney disease
This therapeutic nihilism is also of relevance in an 
ongoing, very controversial—in part highly emotional—
debate about the value of oral anticoagulation in ESKD. 
Some of the protagonists accuse the others to harm the 
patients by administering a dangerous VKA, while their 
opponents point out that withholding the oral anticoag-
ulation is not justified and actually harms the patients. 
In fact, currently no one has reliable and adequate data: 
while especially the large-sized trials with non-VKA oral 
anticoagulants have shown that oral anticoagulation is 
effective and safe even down to an eGFR of 25 or 30 mL/
min,29–32 below this threshold the available data are mark-
edly limited regarding both quantity and quality.
Numerous small and retrospective studies have tried to 
assess the value of VKA in haemodialysis as summarised 
previously.19 33 However, all retrospective studies suffer 
from a significant selection bias of the patients treated 
with anticoagulation.7 A meta-analysis of 11 observational 
studies with 25 407 AF patients with EKSD found warfarin 
to significantly lower stroke rate but to have no effect on 
mortality.34
Larger, unbiased observational information exists: 
in an analysis of the hospital database of Denmark with 
>130 000 AF patients of whom 3587 (2.7%) had non-end-
stage CKD and 901 (0.7%) required renal replacement 
therapy at the time of inclusion,35 warfarin treatment was 
associated with a significantly decreased risk of stroke or 
systemic thromboembolism in patients with CKD and 
ESKD. VKA monotherapy and combination of VKA and 
ASA were associated with an increased risk of bleeding. 
Platelet inhibitors such as ASA did not reduce thrombo-
embolic events but were associated with a high rate of 
adverse effects as also shown by others.35 36 Therefore, 
platelet inhibition does not seem to be a viable treatment 
in patients with AF and ESKD. A more recent report on 
an updated version of the same data set included mean-
while 150 000 patients37 with an increased risk of stroke 
and systemic embolism (CHA2DS2-VASc score ≥2); their 
data showed that VKA therapy was significantly associated 
with lower all-cause mortality in patients with CKD (HR 
0.64, 95% CI 0.60 to 0.69) and in those with ESKD (HR 
0.85, 95% CI 0.72 to 0.99).
Another very recent publication from the same group 
has shown that time in therapeutic range (TTR) is of 
special importance in patients with reduced eGFR.38 This 
aspect of TTR is included in AXADIA and the INR will be 
assessed and documented thoroughly.
All of these analyses do yet not allow an evidence-based 
decision how to treat haemodialysis patients to reduce 
their immense risk of stroke, systemic and venous throm-
boembolic events, bleedings and cardiovascular death. 
A recently started trial in the USA (RENAL-AF,  clinical-
trial. gov identifier NCT02942407) comparing apixaban 
(5 mg twice daily) with warfarin (INR 2–3) in patients 
with AF and ESKD on haemodialysis will add knowledge 
regarding safety and efficacy of apixaban in this critically 
ill patients’ cohort.
Calciphylaxis with VKAs
Patients on maintenance haemodialysis treatment are 
often vitamin K-deficient which may be linked with 
advanced arterial calcifications due to a number of 
preclinical and few clinical studies.39–42 However, a very 
recent clinical trial failed to demonstrate any negative 
impact of warfarin on calcification,43 while also one older 
but large observational study from the US renal data 
system could not find any difference in overall survival 
between patients with and without warfarin.44 Although 
no explicit substudy regarding vascular calcifications is 
planned within AXADIA, major cardiovascular events due 
to calcifications are included in the efficacy end points 
of the trial and will be compared with patients receiving 
VKA and those under apixaban.
limitations
With regard to the fact that this is an investigator-initiated 
trial, financial resources are spare and had to be applied 
thoroughly. Therefore, the number of patients which 
will be included to determine a significant difference 
regarding the safety end points is considered to be suffi-
cient. A security margin of 20% should compensate the 
complete lack of any previous data in this field. Neverthe-
less, a larger cohort would have been desirable in order 
to identify differences concerning the efficacy end points.
The trial is adequately designed and powered to 
answer the question whether apixaban is non-inferior 
or possibly even superior to phenprocoumon regarding 
safety and maybe also regarding efficacy. However, since 
there is no control arm without any anticoagulation 
regime, the trial will provide evidence which type of 
anticoagulation to prefer if indicated (and if intended 
by the treating physician) —but not, whether any oral 
anticoagulation should be given at all in haemodialy-
sis-dependent patients with AF.
Fistula bleeding events may be induced either by punc-
turing for dialysis procedure or by anticoagulation. No 
differentiation will be made with regard to the under-
lying cause of this outcome measure. Therefore, bleeding 
events may be overestimated. But due to the randomised 
design of the trial, fistula bleedings are expected to occur 
with equal distribution in both trial arms.
Finally, the trial is designed as an open-label trial due to 
required regular dose adjustments for phenprocoumon 
based on INR measurements.
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ConClusIon
The AXADIA trial will belong to the first randomised 
trials to compare two different regimens of anticoagu-
lation in patients on maintenance haemodialysis. It will 
clarify if the novel direct factor Xa antagonist apixaban 
will be comparable or even be superior to a standard 
therapy with the VKA phenprocoumon in patients with 
paroxysmal, persistent or permanent AF. Finally, the 
AXADIA trial is a pilot study whose results shall provide 
the basis for a larger outcome study.
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